Patent US3797865A successfully refreshed from Google Patents.
Patent US4808611A successfully refreshed from Google Patents.
US4808611A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of interleukin-1 to induce development of multipotent hemopoietic cell populations
Assignee: Immunex Corp
•
Filing: 1986-07-30
•
Granted: 1989-02-28
•
Expires: 2006-07-30
Abstract
Abstract Interleukin-1, in conjunction with one or a mixture of selected colony-stimulating factors, is capable of inducing the development of primitive multipotent hemopoietic cell populations.
Inventors
- 👤 David J. Cosman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 08:37
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/545; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/20; A61K38/2006; A61P; A61P35/00; A61P35/02
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
36 words
A method of inducing proliferation and differentiation of hemopoietic stem cells in a mammal, comprising administering to the mammal an effective quantity of interleukin-1 (IL-1) in conjunction with an effective quantity of a colony stimulating factor.
Claim 2
Independent Claim
36 words
A method of inducing proliferation and differentiation of hemopoietic stem cells in a mammal, comprising administering to the mammal an effective quantity of interleukin-1 (IL-1) in conjunction with an effective quantity of a colony stimulating factor.
Claim 3
Dependent Claim
24 words
A method according to claim 1, wherein the colony stimulating factor is selected from the group consisting of GM-CSF, CSF-1, G-CSF, erythropoietin, and EPA.
Claim 4
Dependent Claim
11 words
A method according to claim 2, wherein the IL-1 is IL-1α.
Claim 5
Dependent Claim
12 words
A method according to claim 3, wherein the IL-1 is human IL-1α.
Claim 6
Dependent Claim
13 words
A method according to claim 4, wherein the IL-1 is recombinant human IL-1α.
Claim 7
Dependent Claim
22 words
A method according to claim 5, wherein the colony stimulating factor is selected from the group consisting of GM-CSF, CSF-1, and G-CSF.
Claim 8
Dependent Claim
11 words
A method according to claim 2, wherein the IL-1 is IL-1β.
Claim 9
Dependent Claim
12 words
A method according to claim 7, wherein the IL-1 is human IL-1β.
Claim 10
Dependent Claim
13 words
A method according to claim 8, wherein the IL-1 is recombinant human IL-1β.
Claim 11
Dependent Claim
22 words
A method according to claim 9, wherein the colony stimulating factor is selected from the group consisting of GM-CSF, CSF-1, and G-CSF.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-02-28 | 1992-08-29 | 1993-02-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-02-28 | 1996-08-29 | 1997-02-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-02-28 | 2000-08-29 | 2001-02-28 | $7700.00 | Window Closed / Lapsed |